Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group

[1]  Y. Kanda,et al.  Efficacy and safety of tazobactam/piperacillin as an empirical treatment for the patients of adult and child with febrile neutropenia in Japan. , 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[2]  John Moore,et al.  Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. , 2013, The Lancet. Infectious diseases.

[3]  C. Viscoli,et al.  ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients , 2012, Bone Marrow Transplantation.

[4]  K. Sepkowitz,et al.  Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .

[5]  K. Sepkowitz,et al.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  T. Naoe,et al.  Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group , 2011, International journal of hematology.

[7]  T. Naoe,et al.  Management of infection in patients with acute leukemia during chemotherapy in Japan: questionnaire analysis by the Japan Adult Leukemia Study Group , 2009, International journal of hematology.

[8]  Y. Kanda,et al.  Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients. , 2007, The Journal of antimicrobial chemotherapy.

[9]  K. Tamura.  Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group. , 2005, International journal of antimicrobial agents.

[10]  G. Verhoef,et al.  Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  L. Leibovici,et al.  Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients , 2005, Annals of Internal Medicine.

[12]  K. Klose,et al.  Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[13]  T. Masaoka.  Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  R. Ohno,et al.  Antimicrobial prophylaxis in febrile neutropenia. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  R. Ohno,et al.  Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  M. Paesmans,et al.  Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  T. Calandra,et al.  Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .

[18]  T. Miyazaki,et al.  Efficacy of granulocyte colony‐stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study , 2002, British journal of haematology.

[19]  M. Laseur,et al.  A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. , 2000, The Journal of antimicrobial chemotherapy.

[20]  A. Ganser,et al.  A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia , 1997 .

[21]  L. Young,et al.  1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  A. Ganser,et al.  A Randomized , Double-Blind , Placebo-Controlled , Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia , 1997 .

[23]  C. Bloomfield,et al.  Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia. , 1996, Blood.

[24]  L. Young,et al.  From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. , 1990, The Journal of infectious diseases.